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ill population has been difﬁcult. OBJECTIVES: To explore 
protective and risk factors for a later severe violent offense 
(i.e. forensic admission) among the mentally ill (schizophrenics)
and to do thorough investigation for appropriate models.
METHODS: Between 1998–2000, 308 forensic and general psy-
chiatry patients were recruited to case-control study in Canada,
Finland, Germany, and Sweden. An innovative greedy naive
Bayesian (NB) algorithm P-Course was utilized to search gener-
alized factors from national datasets into a merger model (naive
Bayesian fusion). The evidence was assessed with posterior odds
(PO) and the predictions with accuracy, diagnostic odds ratio
(DOR), area under ROC curve (AUC), Gini coefﬁcient and log-
arithmic loss (log score). The models were tested using leave-one-
out cross-validations and substitution procedures in which data
was divided into separate teaching and test sets. RESULTS: The
most inﬂuential predictive risk factors for violent offence include
violent behavior prior to the index hospitalization (PO 11.8;
95% credibility interval 5.9–30.3), biological father’s conviction
(9.4; 4.7–20.0), no use of psychotropic medications before the
age of 18 (7.7; 4.3–16.5), and biological father’s substance abuse
(2.6; 1.7–4.1). The merger model indicates very good discrimi-
native power (DOR from 30.25; AUC from 0.82; Gini from
0.63; log score below 0.65) as well as robustness and accuracy
(Canadian 82.5%; Swedish 87.1%) for the test sets. CONCLU-
SIONS: The characteristics of biological father and no use of psy-
chopharmaceuticals before the age of 18 among mentally ill were
related to committing a later severe violent offense. The explo-
ration and predictions were carried out with P-Course and the
multinational merger NB model indicated high discriminatory
power and robustness compared to previous studies.
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OBJECTIVES: While the prescription of SSRIs and SNRIs for
major depressive disorder (MDD) has increased, resource utili-
sation has rarely been studied in large populations in real-life set-
tings. The purpose of this study was to assess resource utilisation
associated with the prescription of antidepressants in an adult
population with MDD in primary care using data extracted 
from the General Practitioner Research Database (GPRD).
METHODS: We conducted a retrospective study using the
GPRD. Patients diagnosed with MDD aged 18–70 having a new
prescription of paroxetine, ﬂuoxetine, citalopram, sertraline, esc-
italopram, venlafaxine or amitriptyline between January 1, 2001
and September 30, 2003 and not having received antidepressant
treatment in the previous six-months were included. Analyses
focused on ﬁrst depressive episodes for each patient. Patient,
disease and treatment characteristics, GP visits, referrals and hos-
pitalisations were analysed. RESULTS: Information was gath-
ered from over 59,000 patients. Mean age of patients was 39
and 69% were female. 57% suffered from mild depression, 37%
moderate and 6% severe. Mean time of a depressive episode was
about 6 months. Patients visited a GP on average 10 times per
episode. There was a trend between frequency of GP visits and
severity per episode (10 for mild, 11 for moderate and 12 for
severe). 2% of patients were referred to psychiatric specialists.
Compared with patients under SSRIs, there were 80% more
referrals under SNRIs and 20% fewer under TCAs. 4% of all
patients were hospitalized: 60% more hospitalisations under
SNRIs and 40% more under TCAs compared with SSRIs. CON-
CLUSIONS: This GPRD-based study provides better knowledge
of medical resource use in depressed patients in the UK. It should
promote better prescription strategies and use of antidepressants
in primary care.
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OBJECTIVES: To assemble data on resource use for patients
with schizophrenia across several European countries.
METHODS: Physicians in 5 European countries who prescribed
antipsychotics for ≥15 patients with schizophrenia within the
preceding 3 months were invited to complete a questionnaire
concerning their patients’ clinical status and resource use.
Resource use was assessed in terms of frequency of psychiatric
hospitalization, length of last completed hospital stay, intensive
care unit use, outpatient visits, and number of current medica-
tions. RESULTS: Data were obtained from 704 physicians treat-
ing 6569 patients from France (n = 1492), Germany (n = 1439),
Italy (n = 1003), Spain (n = 1310), and the UK (n = 1326). Italy
(77%), Spain (75%), and Germany (72%) had larger percent-
ages of patients with at least one psychiatric hospitalization in
the previous year than did France (56%) and the UK (55%).
Mean length of hospital stay varied signiﬁcantly across countries,
from 19.4 days in Italy to 67.5 days in the UK, and was signif-
icantly longer for the subset of patients in whom negative symp-
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